Immune-Mediated Skin Disease

2008 ◽  
pp. 122-171
Author(s):  
Michael Day ◽  
Susan Shaw
Keyword(s):  
Skin Disease ◽  
Immune Mediated

Immune-mediated skin disease in the dog and cat

1993 ◽  
Vol 109 (4) ◽  
pp. 395-407 ◽  
Author(s):  
M.J. Day ◽  
L. Hanlon ◽  
L.M. Powell
Keyword(s):  
Skin Disease ◽  
Immune Mediated

scholarly journals Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis

2020 ◽  
Vol 12 (2) ◽  
pp. 132-137
Author(s):  
Mary Catherine G. Pangilinan ◽  
Peerada Sermswan ◽  
Pravit Asawanonda
Keyword(s):  
Monoclonal Antibodies ◽  
Immune System ◽  
Hiv Infection ◽  
Opportunistic Infection ◽  
Treatment Option ◽  
Skin Disease ◽  
Hiv Patients ◽  
Immune Mediated ◽  
Erythrodermic Psoriasis ◽  
Promising Treatment

Psoriasis is an immune-mediated skin disease with various presentations. HIV infection affects the immune system and aggravates psoriasis lesions. Therefore, psoriasis management in HIV patients poses a great challenge for dermatologists. In this report, 2 HIV patients with erythrodermic psoriasis received anti-IL-17 and experienced significant clearance of lesions. No recurrence or opportunistic infection was noted. In conclusion, anti-IL-17 monoclonal antibodies are an effective and promising treatment option for HIV-infected patients with psoriasis.

scholarly journals Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models

2021 ◽  
Vol 5 (7) ◽  
pp. 581-589
Author(s):  
Yan Xing ◽  
Katherine A. Chu ◽  
Jyoti Wadhwa ◽  
Wei Chen ◽  
Jiang Zhu ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Skin Disease ◽  
Kinase Inhibitor ◽  
Disease Models ◽  
Immune Mediated ◽  
Bruton Tyrosine Kinase

Psoriasis treatment

2018 ◽  
Author(s):  
Ami Saraiya ◽  
Deep Joshipura ◽  
Alice Gottlieb
Keyword(s):  
Skin Disease ◽  
Biological Therapy ◽  
Topical Therapy ◽  
Treatment Options ◽  
Evidence Based ◽  
Treatment Algorithms ◽  
Immune Mediated ◽  
Biological Treatments ◽  
The Impact ◽  
Disease Location

Psoriasis is an immune-mediated skin disease that is associated with various factors, including genetics, stress, infections, and environmental triggers. Numerous treatment options exist for plaque psoriasis including topical therapy, phototherapy, systemic therapy, and biological therapy. In order to select a treatment for a patient, a clinician must consider many aspects. First, one must assess the impact and burden of the disease on a patient as well as a patient’s expectations from therapy. Other important factors to consider include the severity of skin disease, location of psoriatic plaques, comorbidities and presence of psoriatic arthritis, efficacy of different treatments, potential side-effects, safety, and cost. In this chapter, an evidence-based review is presented on the treatment armamentarium for psoriasis as well as new biological treatments and those under investigation. In order to guide practitioners, several treatment algorithms are provided and others are referenced from the literature.

Cardiovascular Risk in Psoriasis: Current State of the Art

2018 ◽  
Vol 17 (1) ◽  
pp. 85-91 ◽  
Author(s):  
Giuseppe Dattilo ◽  
Francesco Borgia ◽  
Claudio Guarneri ◽  
Matteo Casale ◽  
Roberto Bitto ◽  
...  
Keyword(s):  
Risk Factor ◽  
Cardiovascular Risk ◽  
Skin Disease ◽  
Independent Risk Factor ◽  
Clinical Laboratory ◽  
State Of The Art ◽  
Mortality And Morbidity ◽  
Current State ◽  
Immune Mediated

Psoriasis (Pso) is a chronic inflammatory immune-mediated skin disease associated with several comorbidities. Despite the growing number of studies providing evidence for the link between Pso and Cardiovascular (CV) disorders, there are still many unsolved questions, dealing with the role of the skin disease as an independent risk factor for CV events, the influence of Pso severity and duration on CV damage, the presence of Psoriatic Arthritis (PsA) as a predictor of increased CV mortality and morbidity and the detection of reliable clinical, laboratory and/or instrumental parameters to stratify CV risk in psoriatic patients. Moreover, it remains to clarify if the early treatment of the dermatosis may lower CV risk. In this paper we will try to provide answers to these queries in the light of the updated data of the literature.

Sign in / Sign up

Export Citation Format

Share Document